Cardiovascular disease (CVD) is a leading cause of morbidity and mortality. In the gulf countries specially in Saudi Arabia Diabetes type 2 is becoming the highest in the world, affecting around 30% of adults. In fact, diabetes is associated with an increased risk of cardiovascular disease (CVD). The management of diabetic dyslipidemia, a well-recognized and modifiable risk factor, is therefore a key factor in the multifactorial process to prevent CVD in individuals with type 2 diabetes. Several meta-analysis studies have clearly demonstrated the effects of statin therapy. To investigate the adherence of simvastatin in patients with type 2 diabetes. A descriptive case study of 168 diabetic patients was conducted in Hera General Hospital. Data were retrieved from medical records from January 2018 until December 2018. Data analysis was performed using SPSS software. Most of the sample population (95%) was older than 40 years of age. Almost all patients (97%) were on statin therapy. The treatment target for LDL-c < 2.5 mmol/l was achieved in 42 (21%) patients. Diabetic men were more likely than diabetic women to receive a statin prescription (P<0.05). Data from 2018 showed that diabetic HGH patients showed only a small proportion of patients with diabetes have met the LDL-c treatment goal. This underline the need for better monitoring, better use of available medicines and new treatment options for better quality of life.

Keywords: Simvastatin, Diabetes type 2, CVD, Dyslipidemia